Publications

2018

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer’s disease.Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O. Neurobiol Aging. 2018 Nov;71:81-90. Epub 2018 Jul 11.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.  Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, Fox NC, Sanchez-Valle R, Grau-Rivera O, Gelpi E, Seelaar H, Papma JM, van Swieten JC, Hodges JR, Leyton CE, Piguet O, Rogalsky EJ, Mesulam MM, Koric L, Nora K, Pariente J, Dickerson B, Mackenzie IR, Hsiung GR, Belliard S, Irwin DJ, Wolk DA, Grossman M, Jones M, Harris J, Mann D, Snowden JS, Chrem-Mendez P, Calandri IL, Amengual AA, Miguet-Alfonsi C, Magnin E, Magnani G, Santangelo R, Deramecourt V, Pasquier F, Mattsson N, Nilsson C, Hansson O, Keith J, Masellis M, Black SE, Matías-Guiu JA, Cabrera-Martin MN, Paquet C, Dumuirger J, Teichmann M, Sarazin M, Bottlaender M, Dubois B, Rowe CC, Villemagne VL, Vandenberghe R, Granadillo E, Teng E, Mendez M, Meyer PT, Frings L, Lleó A, Blesa R, Fortea J, Seo SW, Diehl-Schmid J, Grimmer T, Frederiksen KS, Sánchez-Juan P, Chételat G, Jansen W, Bouchard RW, Robert L Jr, Visser PJ, Ossenkoppele R. Ann Neurol. 2018 Sep 26. [Epub ahead of print]

Parkinson’s disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study.  Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K. J Neurol Neurosurg Psychiatry. 2018 Sep 25. pii: jnnp-2018-318956. [Epub ahead of print]

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.  Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O. JAMA. 2018 Sep 18;320(11):1151-1162.

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders. Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O. Sci Rep. 2018 Sep 5;8(1):13276.

Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology.  Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, Teipel SJ; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2018 Sep 1;141(9):2755-2771.

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study. Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jögi J, Palmqvist S, Stomrud E, Hansson O. Alzheimers Res Ther. 2018 Aug 7;10(1):77.

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O. Neurology. 2018 Aug 28;91(9):e867-e877. Epub 2018 Jul 27.

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake. Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, Schöll M. J Cereb Blood Flow Metab. 2018 Aug 3:271678X18791430. [Epub ahead of print]

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: A Review.  Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K. Alzheimers Dement. 2018 Jun 22. pii: S1552-5260(18)30162-6.

Is longitudinal tau PET ready for use in Alzheimer’s disease clinical trials?  Hansson O, Mormino EC. Brain. 2018 May 1;141(5):1241-1244.

Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic ReviewYgland E, van Westen D, Englund E, Rademakers R, Wszolek ZK, Nilsson K, Nilsson C, Landqvist Waldö M, Alafuzoff I, Hansson O, Gustafson L, Puschmann A.Alzheimers Res Ther. 2018 Jan 9;10(1):2.

Alzheimer’s Disease Neuroimaging Initiative. Amyloid pathology in the progression to mild cognitive impairment. Insel PS, Hansson O, Mackin RS, Weiner M, Mattsson N. Neurobiol Aging. 2018 Apr;64:76-84.

Altered structural network organization in cognitively normal individuals with amyloid pathology. Voevodskaya O, Pereira JB, Volpe G, Lindberg O, Stomrud E, van Westen D, Westman E, Hansson O. Neurobiol Aging. 2018 Apr;64:15-24..

Comparing 18F-AV-1451 with CSF T-tau and P-tau for diagnosis of Alzheimer’s disease. Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel P, Hagerstrom D, Olsson T, Zetterberg H, Blennow K, Jögi J, Hansson O. Neurology. 2018 Jan 30;90(5):e388-e395.

Amyloid network topology characterizes the progression of Alzheimer’s disease during the pre-dementia stages. Pereira JB, Strandberg TO, Palmqvist S, Volpe G, Westen Dv, Westman E, Hansson O, for the Alzheimer’s Disease Neuroimaging Initiative. Cerebral Cortex.  2018 Jan 1;28(1):340-349.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A,  Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber  J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY,  Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A,  Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M,  Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici  GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT,  Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group,
Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel  H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen  AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF,  Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P,  Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V,  Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak  GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez
E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L,  Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar  G, Wallin ÅK, Wiltfang J, Zetterberg H. JAMA   Psychiatry. 2018 Jan 1;75(1):84-95. 

Amyloid Network Topology Characterizes the Progression of Alzheimer’s Disease During the Predementia Stages.Pereira JB, Strandberg TO, Palmqvist S, Volpe G, van Westen D, Westman E, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Cereb Cortex. 2018 Jan 1;28(1):340-349.

Amyloid blood biomarker detects Alzheimer’s disease. Nabers A, Perna L, Lange J, Mons U, Schartner J, Güldenhaupt J, Saum KU, Janelidze S, Holleczek B, Rujescu D, Hansson O, Gerwert K, Brenner H. EMBO Mol Med. 2018 Apr 6. pii: e8763.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer’s disease. Mattsson N, Groot C, Jansen WJ, Landau S, Villemagne V, Engelborghs S, Mintun M, Lleo A, Molinuevo JL, Jagust W, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimella
R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem  MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi  Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere  K, de Leon M, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC,  Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe  CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E,  Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC,  Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC,  Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL,  Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM,  Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier  WM, Scheltens P, Visser PJ, Ossenkoppele R.  Alzheimers Dement. 2018 Mar 27. pii: S1552-5260(18)30063-3. 

Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms. Owens-Walton C, Jakabek D, Li X, Wilkes FA, Walterfang M, Velakoulis D, van Westen D, Looi JCL, Hansson O. Psychiatry Res. 2018 Mar 7. pii: S0925-4927(17)30213-5.

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies.  Smith R, Schöll M, Londos E, Ohlsson T, Hansson O.
Sci Rep. 2018 Mar 16;8(1):4717. 

CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke
V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw
LM; Swedish BioFINDER study group; Alzheimer’s Disease Neuroimaging Initiative.
Alzheimers Dement. 2018 Mar 1. pii: S1552-5260(18)30029-3.

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease. Patra K, Soosaipillai A, Sando SB, Lauridsen C, Berge G, Møller I, Grøntvedt  GR, Bråthen G, Begcevic I, Moussaud S, Minthon L, Hansson O, Diamandis EP, White  LR, Nielsen HM.  Alzheimers Res Ther. 2018 Jan 29;10(1):9. 

Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study. Surova Y, Nilsson M, Lampinen B, Lätt J, Hall S, Widner H, van Westen D, Hansson O. Neuroradiology. 2018  Mar;60(3):247-254. Epub 2018 Jan 24.

Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later Nägga K, Gustavsson AM, Stomrud E, Lindqvist D, van Westen D, Blennow K,  Zetterberg H, Melander O, Hansson O. Neurology. 2018 Jan   2;90(1):e73-e81. Epub 2017 Dec 1.

Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. Hansson O, Palmqvist S, Ljung H, Cronberg T, van Westen D, Smith R. Alzheimers Dement. 2018 Jan;14(1):54-61.

2017

Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer’s Disease.Pereira JB, van Westen D, Stomrud E, Strandberg TO, Volpe G, Westman E,
Hansson O. Cereb Cortex. 2017 Oct 3:1-12.

The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer’s disease. Svärd D, Nilsson M, Lampinen B, Lätt J, Sundgren PC, Stomrud E, Minthon L, Hansson O, van Westen D. PLoS One. 2017 Sep 21;12(9):e0185239.  eCollection 2017.

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease. Skillbäck T, Mattsson N, Hansson K, Mirgorodskaya E, Dahlén R, van der Flier W, Scheltens P, Duits F, Hansson O, Teunissen C, Blennow K, Zetterberg H, GobomJ.  Sci Rep. 2017
Oct 17;7(1):13333.

CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Skillbäck T, Delsing L, Synnergren J, Mattsson N, Janelidze S, Nägga K, Kilander L, Hicks R, Wimo A, Winblad B, Hansson O, Blennow K, Eriksdotter M, Zetterberg H. Neurobiol Aging. 2017 Nov;59:1-9. Epub 2017 Jul 11.

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. Lautner R, Insel PS, Skillbäck T, Olsson B, Landén M, Frisoni GB, Herukka SK,  Hampel H, Wallin A, Minthon L, Hansson O, Blennow K, Mattsson N, Zetterberg H.  Alzheimers Res Ther. 2017 Oct 23;9(1):87.

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer’s Disease and Parkinsonian Disorders.  Sjödin S, Hansson O, Öhrfelt A, Brinkmalm G, Zetterberg H, Brinkmalm A, Blennow K. Proteomics Clin Appl. 2017  Dec;11(11-12). Epub 2017 Nov 2. 

Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Pereira JB, Westman E, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Neurobiol Aging. 2017 Oct;58:14-29. Epub 2017 Jun 17.

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O. Nature communications. 2017 Oct 31;8(1):1214.

Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O.  JAMA Neurology 2017 Dec 1;74(12):1492-1501.

Atrophy of the posterior subiculum is associated with memory impairment, tau- and Aβ pathology in non-demented individuals. Lindberg O, Mårtensson G, Stomrud E, Palmqvist S, Wahlund L-O, Westman E, Hansson O. Frontiers in Aging Neuroscience. 2017 Sep 20;9:306.

In vivo retention of (18)F-AV-1451 in corticobasal syndrome. Smith R, Schöll M, Widner H, van Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O. Neurology. 2017 Aug 22;89(8):845-853.

Distinct 18F-AV- 1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S, Ohlsson T, Jögi J, Smith R, Hansson O. Brain 2017 Sep 1;140(9):2286-2294.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O. EMBO Mol Med. 2017 Sep;9(9):1212-1223.

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40). Vanderstichele H, Demeyer L, Janelidze S, Coart E, Stoops E, Mauroo K, Herbst V, François C, Hansson O. Alzheimers Res Ther. 2017 Jun 6;9(1):40.

Psychometric testing of a Swedish version of the Apathy Evaluation Scale. Johansson M, Johansson P, Stomrud E, Hagell P, Hansson O. Nord J Psychiatry. 2017 Aug;71(6):477-484.

The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Ferreira D, Hansson O, Barroso J, Molina Y, Machado A, Hernández-Cabrera JA, Muehlboeck JS, Stomrud E, Nägga K, Lindberg O, Ames D, Kalpouzos G, Fratiglioni L, Bäckman L, Graff C, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Soininen H, Lovestone S, Ahlström H, Lind L, Larsson EM, Wahlund LO, Simmons A, Westman E; and for the AddNeuroMed consortium, for the Alzheimer’s Disease Neuroimaging Initiative (ADNI).; Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) research group. Hippocampus. 2017 Jun;27(6):653-667.

Tau oligomers in cerebrospinal fluid in Alzheimer’s disease. Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, Zetterberg H, Galasko D, Blennow K, Kayed R. Ann Clin Transl Neurol. 2017 Mar 1;4(4):226-235.

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.  Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K; Swedish BioFINDER study.  Neurology. 2017 Mar 7;88(10):930-937

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype.  Janelidze S, Hertze J, Nägga K, Nilsson K, Nilsson C; Swedish BioFINDER Study Group., Wennström M, van Westen D, Blennow K, Zetterberg H, Hansson O.  Neurobiol Aging. 2017 Mar;51:104-112.

Tau Pathology Distribution in Alzheimer’s disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. Hansson O, Grothe MJ, Strandberg TO, Ohlsson T, Hägerström D, Jögi J, Smith R, Schöll M. Front Neurosci. 2017 Mar 31;11:167.

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Smith R, Schöll M, Honer M, Nilsson CF, Englund E, Hansson O. Acta Neuropathol. Acta Neuropathol. 2017 Jan;133(1):149-151.

Increased basal ganglia binding of of 18F-AV-1451 in patients with progressive supranuclear palsy. Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hägerström D, Jögi J, Borroni E, Schöll M, Honer M, Hansson O. Mov Disord. 2017 Jan;32(1):108-114.

Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease. Habchi J, Chia S, Limbocker R, Mannini B, Ahn M, Perni M, Hansson O, Arosio P, Kumita JR, Challa PK, Cohen SI, Linse S, Dobson CM, Knowles TP, Vendruscolo M. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):E200-E208.

Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology Hahn A, Schain M, Erlandsson M, Sjölin P, James GM, Strandberg OT, Hägerström D, Lanzenberger R, Jögi J, Olsson TG, Smith R, Hansson O,   J Nucl Med. 2017 Apr;58(4):623-631.

2016

Plasma tau in Alzheimer disease   Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K   Neurology. 2016 Oct 25;87(17):1827-1835.

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, Englund E, Hansson O. Brain. 2016 Sep;139(Pt 9):2372-9.

Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis? Palmqvist S, Mattsson N, Hansson O. Brain. 2016 Nov 1;139(11):e61. 

Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease. Surova Y, Lampinen B, Nilsson M, Lätt J, Hall S, Widner H; Swedish BioFINDER study, van Westen D, Hansson O. PLoS One. 2016 Jun 30;11(6):e0157755.

Brain activity and Alzheimer’s disease: a complex relationship. Hansson O, Gouras G. Brain. 2016 Aug;139(Pt 8):2109-10.

Reference measurement procedure for CSF Aβ1-42 and the CSF Aβ1-42 /Aβ1-40 ratio – a cross-validation study against Amyloid PET. Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, Hansson O, Blennow K. J Neurochem. 2016 Aug 31.

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes. Vanderstichele HM, Janelidze S, Demeyer L, Coart E, Stoops E, Herbst V, Mauroo K, Brix B, Hansson O. J Alzheimers Dis. 2016 May 31;53(3):1121-32.

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease. Andersson CH, Hansson O, Minthon L, Andreasen N, Blennow K, Zetterberg H, Skoog I, Wallin A, Nilsson S, Kettunen P. J Alzheimers Dis. 2016 Jul 1;53(4):1353-63.

Plasma β-amyloid in Alzheimer’s disease and vascular diseaseJanelidze S,  Stomrud E,  Palmqvist S,   Zetterberg H,  van Westen D,  Jeromin A,  Song L,  Hanlon D,  Tan Hehir C,  Baker D,  Blennow K,  Hansson O. Scientific Report. 2016 May 31;6:26801.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease.
Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. EMBO Mol Med. 2016 Aug 17.

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PETvan Westen D, Lindqvist D, Blennow K, Minthon L, Nägga K, Stomrud E, Zetterberg H, Hansson O. Scientific Reports. 2016 Feb 9;6:20709.

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer’s Disease Patient with Presenilin-1 Mutation. Smith R, Wibom M, Olsson T, Hägerström D, Jögi J, Rabinovici GD, Hansson O. J Alzheimers Dis. 2016 Jan 21;51(2):339-43.

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Palmqvist S, Mattsson N, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2016 Apr;139(Pt 4):1226-36.

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease. Hall S, Surova Y, Öhrfelt A; Swedish BioFINDER Study, Blennow K, Zetterberg H, Hansson O. Movement Disorders. 2016 Feb 16.

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis. Mattsson N, Insel P, Palmqvist S, Stomrud E, van Westen D, Minthon L, Zetterberg H, Blennow K, Hansson O. Nature Communications. 2016 Mar 7;7:10918.

Early myo-inositol changes may precede Aβ pathology and relate to APOE genotype in Alzheimer disease. O Voevodskaya1, PC Sundgren, O Strandberg, H Zetterberg, L Minthon MD, K Blennow, L-O Wahlund, for the Swedish BioFINDER study group, E Westman and O Hansson. Neurology. 2016 May 10;86(19):1754-61.

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios improve the diagnostic accuracy for Alzheimer’s diseaseS Janelidze, H Zetterberg, N Mattsson, S Palmqvist, H Vanderstichele, the Swedish BioFINDER study, O Lindberg, D van Westen, E Stomrud, L Minthon, K Blennow, O Hansson. Ann Clin Transl Neurol. 2016 Jan 1;3(3):154-65.

 

2015

Comparison of Amyloid PET and CSF Biomarkers for Identifying Early Alzheimer’s Disease.
Palmqvist S, Zetterberg H, Mattsson N, Johansson P, for the Alzheimer’s Disease Neuroimaging Initiative, Minthon M, Blennow K, Olsson M, for the Swedish BioFINDER study group, Hansson O. Neurology. 2015 Oct 6;85(14):1240-9.

Increased cerebrospinal fluid biomarkers of angiogenesis in Parkinson’s disease. Janelidze S, Lindqvist D, Francardo V, Hall S,Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, the Swedish BioFINDER study, Cenci A, Hansson O. Neurology, 2015 Nov 24;85(21):1834-42.

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer’s disease: A prospective 9-year study. Stomrud E, Minthon L, Zetterberg H, Blennow K, Hansson O. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2015 1: 4, 403–411.

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patientsWennström M, Hall S, Nägga K, Londos E, Minthon L, Hansson O. Alzheimer’s Research & Therapy. 2015 Oct 5;7(1):63.

Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson’s Disease Dementia. Nilsson M, Szczepankiewicz F, van Westen D, Hansson O. PLoS One. 2015 Nov 3;10(11):e0141825

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease. Silajdzic E, Bjorkqvist M, & Hansson O. BMC Neurol 2015, 15:8.

Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects.
Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2015 Sep;138(Pt 9):2701-15.

Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Surova Y, Nilsson M, Lätt J, Lampinen B, Lindberg O, Hall S, Widner H, Nilsson C, van Westen D, Hansson O. Neuroradiology. 2015 Nov;57(11):1079-91.

Parkinson’s Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. Gallo V, Brayne C, Forsgren L, Barker RA, Petersson J, Hansson O, Lindqvist D, Ruffmann C, Ishihara L, Luben R, Arriola L, Bergareche A, Gavrila D, Erro ME, Vanacore N, Sacerdote C, Bueno-de-Mesquita B, Vermeulen R, Seelen M, Sieri S, Masala G, Ramat S, Kyrozis A, Thricopolou A, Panico S, Mattiello A, Kaaks R, Teucher B, Katzke V, Kloss M, Curry L, Calboli F, Riboli E, Vineis P, Middleton L. Neurodegener Dis. 2015;15(6):331-8.

Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O. Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20.

Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O. Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20.

Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-sectional Cohort Study Evaluating the Effect of Arterial StiffnessAnna-Märta Gustavsson, Erik Stomrud, Kasim Abul-Kasim, Lennart Minthon, Peter M. Nilsson, Oskar Hansson, Katarina Nägga. Cerebrovascular Diseases EXTRA, 2015;5:41–51.

CSF biomarkers and clinical progression of Parkinson disease. Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, and Hansson O. Neurology, 2015 Jan 6;84(1):57-63.

 

2014

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid beta-Amyloid 42Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O. JAMA Neurol. 2014 Oct;71(10):1282-9.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. JAMA Psychiatry. 2014;71(10):1183-91.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls. Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, & Nielsen HM. Acta Neuropathologica 2014, 127(5):633-643.

Flt3 ligand does not differentiate between Parkinsonian disorders. Silajdžić E, Constantinescu R, Holmberg B, Björkqvist M, & Hansson O. Movement Disorders 2014, 29(10):1319-1322.

Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s diseaseHansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM. Alzheimer’s Research & Therapy. 2014;6(3):25.

Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. Nielsen HM, Hall S, Surova Y, Nägga K, Nilsson C, Londos E, Minthon L, Hansson O, Wennström MNielsen HM et al. Journal of Alzheimer’s Disease. 2014;40(2):343-50.

 

2013

Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O. Brain, Behavior, and Immunity. 2013;33:183-9.

Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography. Surova Y, Szczepankiewicz F, Lätt J, Nilsson M, Eriksson B, Leemans A, Hansson O, van Westen D, Nilsson C. PloS One. 2013;8(6):e66022.

Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM. PloS one. 2013;8(1):e53250.

Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseasesNutu M, Bourgeois P, Zetterberg H, Portelius E, Andreasson U, Parent S, Lipari F, Hall S, Constantinescu R, Hansson O, Blennow K. et al. Neuromolecular Medicine. 2013;15(1):169-79.